Children's Medical Center Corporation

Celgene Corporation

Entremed, Inc.

Kimberly A Hunsucker

Jamshed H Shah

Anthony Treston

Robert J D'Amato

Glenn M Swartz

John Rougas

Barry P Conner

Victor S Pribluda

Victor Pribdula

Shawn J Green

Gregory E Agoston

Theresa Marie LaVallee

Christopher J Herbstritt

Xiaoguo H Zhan

Robert J D'amato

Victor Pribluda

The invention provides new and useful analogs of 4-amino-thalidomide. These analogs include S(&#x2212;)-4-amino-thalidomide and R(+)-4-amino-thalidomide. The invention also provides processes for making these analogs. Further, the invention provides methods for inhibiting angiogenesis and treating angiogenesis-associated diseases, including cancer and macular degeneration, by administering these compounds.

Synthesis of 4-amino-thalidomide enantiomers

Method of synthesis of 4-amino-thalidomide enantiomers

The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, nitrogen-substituted thalidomide analogs and di-substituted thalidomide analogs have been shown to inhibit angiogenesis. Importantly, these compounds can be administered orally.

Use of nitrogen substituted thalidomide analogs for the treatment of macular degenerator

Compositions and methods for treating mammalian disease characterized by undesirable angiogenesis by administering derivatives of 2-methoxyestradiol of the general formula: wherein the variables are defined in the specification.

Antiangiogenic agents

Growing community of inventors

Germantown, MD, United States of America

Kimberly A Hunsucker